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Abstract 
A new anti-diabetic drug, pioglitazone, was tested as to whether it could ameliorate the decreased kinase activity of epidermal growth 
factor (EGF) receptor induced by phorbol ester (PMA) in A431 cells. The treatment of A431 cells with PMA decreased the tyrosine 
kinase activity of EGF receptors to 37% of normal in autophosphorylation and to 24% in tyrosine kinase activity toward Glu/Tyr 
synthetic polymers. Co-incubation of the cells with pioglitazone and PMA improved the receptor tyrosine kinase activity to 81% of 
control. Pioglitazone treatment alone did not change the kinase activity of EGF receptors. Pioglitazone did not decrease the 
PMA-activated protein kinase C activity and did not affect the protein tyrosine phosphatases activity in A431 cells. These results suggest 
that pioglitazone may act as a specific antagonist to the inhibitory effect by protein kinase C on the EGF receptor tyrosine kinase. 
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1. Introduction 
Pioglitazone, a thiazolidine derivative, 5-[4-[2-[5-ethyl- 
2-pyridyl]ethoxy]benzyl]-2,4_thiazolidine, was recently de- 
veloped as a new anti-diabetic drug [l]. We found that 
treatment with this drug ameliorated insulin resistance in 
Wistar fatty rats and high fat-fed rats [2,3]. In these 
animals, pioglitazone treatment improved the impaired ty- 
rosine kinase activity of the insulin receptors. Furthermore, 
the drug as well as another similar thiazolidine derivative, 
troglitazone, prevents high-glucose induced desensitization 
of insulin-receptor tyrosine kinase in cultured cell lines 
[4,5]. Although the exact causes for the deterioration of the 
tyrosine kinase activity of insulin receptors in insulin 
resistance are still unknown, several lines of evidence 
indicate that serine and/or threonine phosphorylation of 
the receptors may negatively regulate their tyrosine kinase 
activity [6]. Therefore, protein kinase C, one of the potent 
Abbreviations: EGF, epidermal growth factor; PMA, 4-phorbol 12- 
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serine/threonine kinases, has been proposed to be a modu- 
lator of tyrosine kinase of insulin receptors [7,8]. 
This study was undertaken to investigate whether pi- 
oglitazone treatment could interfere with the inhibitory 
effect of protein kinase C on the EGF receptor tyrosine 
kinase, since it has been established that protein kinase C 
inhibits the tyrosine kinase activity of the EGF receptor 
through phosphorylation of receptor serine/threonine [9- 
1 I]. We also determined the protein tyrosine phosphatase 
(PTPase) activity in the cells treated with pioglitazone, 
because it might directly influence the tyrosine kinase 
activity of EGF receptors [ 121. 
2. Materials and methods 
2. I. Materials 
The human epidermoid carcinoma cell line A431 was 
provided by the Japanese cancer research resources bank. 
Pioglitazone was kindly provided by Takeda Pharmaceuti- 
cal Co. Poly (Glu:Tyr) and 4-phorbol 12 myristate 13- 
acetate (PMA) were purchased from Sigma. [ .y-32PlATP 
( > 185 TBq/mmol) was purchased from Amersham. 
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2.2. Cell culture 
A431 cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM) with 10% fetal calf serum (FCS) and 
antibiotics. Cells were plated in 6-well plates or 10 cm 
dishes. Cells in a confluent monolayer were incubated in 
DMEM with 0.05% FCS for 16 h before the start of each 
experiment. 
1% Triton X-100, 1mM phenylmethylsulfonyl fluoride, 1 
pg/ml aprotinin and 1 pg/rnl leupeptin, pH 7.4) as 
previously described [ 121. The dephosphorylation reaction 
of phosphorylated EGF receptors by PTPase was initiated 
by addition of 50 /Al cell extracts or buffer for 30 min at 
4°C. Tyrosyl phosphorylated proteins were detected by 
PY20 and Amersham ABTS kit and quantified by micro 
plate reader as previously described [ 151. 
2.3. Autophosphorylarion of EGF receptors in A431 cells 2.6. Measurement of protein kinase C activity 
Cells were incubated in MEM containing 1% BSA and 
HEPES 40 mM, pH 7.4 with PMA (500 ng/ml) alone or 
PMA plus pioglitazone for 1 h at 37°C. Following EGF 
(20nM) stimulation for 5 min, the cells were rinsed with 
ice-cold phosphate buffered saline (PBS) containing 2 mM 
sodium vanadate and immediately solubilized in SDS sam- 
ple buffer (50 mM Tris, 2% SDS, 10% glycerol, 0.005% 
bromophenol blue) at 100°C [ 131. The samples were elec- 
torophoretically separated and phosphoproteins were ana- 
lyzed by Western blot with anti-phosphotyrosine antibody 
(PY 20, ICN). EGF dependent phosphorylation of 170 kDa 
protein was observed on the blots and the signal intensity 
was quantified by scanning densitometry EPA 3000 
(Cosmo Bio Co.). 
2.4. Tyrosine kinase activity of purijied EGF receptors 
EGF receptors from A431 cells were partially purified 
with affinity chromatography on wheat germ agglutinin 
(WGA) [ 141. The partially purified receptors (5 pg> were 
incubated with EGF for 30 min at 22°C. Phosphorylation 
reaction was initiated by addition of poly Glu:Tyr (2 
mg/ml) and reaction mixture containing 50 mM Hepes, 
0.1% Triton X-100, 50 PM ATP ([~-32P]ATP, 1 
MBq/tube), 500 PM CTP, 5 mM MnCl,, 12 mM MgCl,. 
Incorporated labeled phosphorus into the polymers was 
determined by filter paper assay [14]. Quantification of the 
EGF receptors was performed by Western blot analysis 
with anti-EGF receptor antibody (UBI). 
A431 cells in 10 cm dish were incubated for 16 h in 
DME with 0.05% FCS. After incubation with PMA or 
pioglitazone, cells were immediately washed two times 
with ice-cold PBS, detached with a cell scraper, and 
transferred to micro centrifuge tubes on ice. The cells were 
homogenized in 0.5 ml ice-cold extraction buffer (20 mM 
Tris, pH 7.5, 0.5 mM EDTA, 25 pg/ml each aprotinin 
and leupepsin) and centrifuged at 100000 X g for 30 min. 
The resulting supematant contained soluble cytosolic pro- 
tein kinase C. The pellet was resolubilized in extraction 
buffer with 0.5% Triton X-100 to solubilize particulate 
membrane protein kinase C. Protein kinase C activity was 
measured using a commercial kit (MBL). The phospho- 
rylation of synthetic peptide, which was similar to the 
phosphorylation site of glial fiblillary acidic protein [16], 
was detected by the anti-phosphorylated peptide antibody 
and peroxidase-conjugated goat anti-mouse IgG. Kinase 
activities were determined by measuring the optical den- 
sity at 492 nm with a micro plate reader. Specific protein 
kinase C activities were determined by subtracting the 
nonspecific activity measured in the presence of 200 PM 
EGTA. 
2.7. Data analysis 
2.5. Measurement of protein tyrosine phosphatase 
(PTPase) activity by immuno-enzyme assay 
Comparisons between PMA treated groups and 
PMA/pioglitazone treated groups were made using Stu- 
dent’s t-test (two-tailed). In addition, for some analysis, 
statistical significance was determined by one factor 
ANOVA and Fisher’s protected least significant difference 
multiple comparison test. 
WGA purified EGF receptors from untreated A43 1 cells 
were incubated with EGF (20 nM) for 30 min at 22°C. 
Phosphorylation of the receptors was initiated by addition 
of 100 PM ATP and 10 mM MgCl, for 10 min at 22°C 
and terminated by addition of coating buffer (15 mM 
Na,CO,, 35 mM NaHC03; pH 9.6). The solution of 
phosphorylated EGF receptors was loaded in each well of 
microtitre plate (Falcon) and allowed to coat overnight at 
4°C. A431 cells were treated with either PMA or pioglita- 
zone as in the autophosphorylation studies. Cell ho- 
mogenate was prepared in buffer A (20 mM Hepes, 150 
mM NaCl, 1 mM EGTA, 1.5mM MgCl,, 10% glycerol, 
3. Results 
3.1. The effect of pioglitazone and PMA on the EGF 
receptor tyrosine kinase 
EGF stimulated autophosphorylation of EGF receptors 
within one minute, and the maximum phosphorylation was 
maintained for 30 min in A431 cells (data not shown). 
PMA treatment inhibited the autophosphorylation of EGF 
receptor to 37% of control (Fig. 1). Pioglitazone alone had 
no effect on autophosphorylation of EGF receptors. How- 
ever, pioglitazone partially ameliorated the inhibited auto- 
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phosphorylation of EGF receptors in the cells treated with 
PMA. The effect of pioglitazone was elicited by IO-* M 
and remained unchanged from IO-’ to 10e5 M of piogli- 
tazone (Fig. 2A and 2B). Pioglitazone treatment also pre- 
vented the impairment of the kinase activity of the EGF 
receptors in the cells treated with PMA (Fig. 3A). Tyrosine 
kinase activity of EGF receptors purified from the cells 
treated with PMA was decreased to 24% of that from 
control cells. EGF receptors from the cells that were 
incubated with both pioglitazone and PMA showed 3.6fold 
increased kinase activity compared to those from the cells 
incubated with PMA alone. However, the amelioration of 
the decreased kinase activity of EGF receptors was partial, 
as shown in the autophosphorylation study. Neither PMA 
nor pioglitazone treatment changed the amount of EGF 
receptor protein in the A431 cells (Fig. 3B). 
3.2. The effect of pioglitazone on the PTPase activity 
We measured the PTPase activity toward phospho- 
rylated EGF receptors in A431 cells. EGF stimulated the 
PTPase activity about 1.6-fold over basal in untreated cells 
(Fig. 4). However, neither PMA nor pioglitazone treatment 
changed the PTPase activity in A431 cell. 
3.3. The effect of pioglitazone on the protein kinase C 
activity 
PMA treatment stimulated protein kinase C activity in 
both cytosol and membrane fraction of A431 cells (Table 
1). However, pioglitazone treatment did not change protein 
PMA _ t t _ 
Pioglitazone _ _ t t 
Fig. 1. Effect of PMA and pioglitazone on EGF-stimulated autophospho- 
rylation in A43 1 cells. Signal intensity from the autophosphorylated EGF 
receptors in the absence and presence of PMA (100 ng/ml) or pioglita- 
zone (10m6 M) on the Western blots was analyzed by densitometry. The 
results are shown as percent of control (mean f SE. of four experiments). 
The autophosphorylation of PMA treated group was significantly de- 
creased versus control group (P < 0.025) and there was a significant 
change between PMA treated group and PMA plus pioglitazone treated 
group (P < 0.05) by Fisher’s multiple comparison test. 
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Fig. 2. Dose dependent effect of pioglitazone on PMA-induced inhibition 
of EGF receptor autophosphorylation in A43 1 cells. A: A43 1 cells were 
treated with various concentrations of pioglitazone in the presence of 
PMA for 1 h. Autophosphorylated EGF receptors were analyzed as 
described in Section 2. In A, a representative autoradiogram is shown. In 
B, the results of densitometric evaluation of the autoradiograph are shown 
(mean+ S.E. of three experiments). The increased signal of the EGF 
receptor phosphorylation in the pioglitazone plus PMA-treated cell sam- 
ples over the PMA-treated cell sample was expressed as persent of the 
signal from total (control) EGF receptor phosphorylation. 
kinase C activity and did not ameliorate the PMA-activated 
protein kinase C activity. 
4. Discussion 
Pioglitazone characteristically ameliorates defective ty- 
rosine kinase activity of the insulin receptor, but does not 
increase the activity of the normal insulin receptor [3,4]. 
This study raised the possibility that the EGF receptor 
tyrosine kinase activity could also be a site of action by the 
thiazolidine derivatives in addition to the insulin receptor 
tyrosine kinase. Furthermore, as what was observed with 
the insulin receptor, pioglitazone did not change EGF 
receptor tyrosine kinase activity from untreated cells and 
only actively modified the activity of the receptors from 
















Fig. 3. Effect of PMA and pioglitazone on EGF receptor tyrosine kinase 
activity and the amount of EGF receptors. A. Tyrosine kinase activities 
toward poly Glu:Tyr 4: 1 were examined in WGA purified EGF receptors 
from the cells treated with PMA (100 ng/ml) or pioglitazone (10e6M) 
for I h. The results are shown as fmol ATP incorporation/30 min per 5 
pg protein (mean + S.E. of four experiments). The tyrosine kinase activ- 
ity between PMA treated group and control group (P < 0.025) and 
between PMA treated group and PMA plus pioglitazone treated group 
(P < 0.05) was significantly different by Fisher’s multiple comparison 
test. There was no significant change between control and PMA plus 
pioglitazone treated group. B. Amount of EGF receptor protein in cells 
treated with PMA or pioglitazone. The signal intensity of EGF receptors 
was analyzed as described in Section 2. Results are shown as mean + S.E. 
of four experiments. There were no significant differences among these 
groups by Fisher’s multiple comparison test. 
derivatives act by attenuating the effects of protein kinase 
C on ligand-regulated tyrosine kinases. 
Kellere et al. [5] reported that another thiazolidine 
derivative, troglitazone, ameliorated the high glucose-in- 
duced desensitization of the insulin receptor kinase and 
suggested that the troglitazone functioned as an inhibitor 
of protein kinase C 161. The current study also suggests 
that protein kinase C activation by PMA treatment de- 
creased EGF receptor tyrosine kinase activity without 
changing receptor number, probably by phosphorylation of 
threonine at the position of 654 [9] and pioglitazone ame- 
liorated this protein kinase C induced inhibitory effect on 
EGF receptor tyrosine kinase activity. However, the piogli- 
tazone does not directly inhibit protein kinase C activation 
by PMA because pioglitazone treatment does not change 
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Fig. 4. Effect of PMA or pioglitazone on PTPase activity in A431 cells. 
After the incubation with PMA, pioglitazone, or both PMA plus pioglita- 
zone for I h, the cells were homogenized and cell lysates from these 
treated cells were added to phosphorylated EGF receptors in microtitre 
plate for 30 min. To evaluate the basal and EGF-stimulated PTPase 
activity, cell lysates from non-treated A431 cells incubated with buffer 
(hatched bar) or 20 nM EGF (open bar) for 5 min were used. Remaining 
tyrosyl phosphorylated receptors were measured as described in Section 
2. The values of phosphorylated protein are presented as percent of 
control and mean+S.E. of three experiments. The control value was 
determined by the measurement of tyrosyl phosphorylation of EGF 
receptors without cell lysates. There were no significant differences 
among these groups without EGF stimulation by Fisher’s multiple com- 
parison test. 
Table 1 
Effect of PMA and pioglitazone on protein kinase C activity in A431 
cells 
Treatment Cvtosol Membrane 
Control 0.104~0.05 0.092+0.12 
PMA 0.140_+0.08 * 0.174_+0.18 * 
PMA/pioglitazone 0.132+0.18 0.168+0.08 * 
Pioglitazone 0.110+0.06 0.092 f 0.04 
A431 cells were treated with PMA, PMA and pioglitazone or pioglita- 
zone alone as described in Section 2. Protein kinase C activity in cytosol 
and membrane fraction was measured and data from 6 experiments are 
presented as the absorbance at 492 nm/lO pg protein (mean+ S.E.). 
There was no significant differences between PMA treated group and 
PMA/pioglitazone treated group by Fisher’s multiple comparison test. 
* P < 0.025 vs. control. 
either cytosolic or membranous protein kinase C activity 
stimulated by PMA. The pioglitazone could not completely 
antagonize the inhibitory effect on the EGF receptor tyro- 
sine kinase activity by PMA. This might be related to the 
fact that PMA bound to the protein kinase C and induced 
an irreversible activation of protein kinase C that might 
partially overcome the antagonizing effect of pioglitazone. 
It has been already shown in the rat fibroblast that the 
troglitazone can also block partially the inhibitory effect 
by PMA on the insulin receptor tyrosine kinase, while it 
antagonizes completely the inhibitory effect of protein 
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kinase C induced by the high-glucose treatment [5]. The 
possibility that the pioglitazone is inhibiting only a certain 
protein kinase C isoenzyme cannot be precluded since 
PMA may activate as many as four different protein kinase 
C subspecies [17]. 
ence, and Culture, Japan, a grant-in-aid for Intractable 
Diseases from the Ministry of Welfare, Japan, a grant from 
Otsuka Pharmaceutical Co. and a grant from the Japanese 
Diabetes Society. 
Alternatively, pioglitazone probably produce its effects 
through inhibiting a signaling process that is activated by 
protein kinase C. In this line, MAP kinase, another 
serine/threonine kinase, negatively regulates EGF receptor 
kinase by activating PTPase in A431 cells and dephospho- 
rylates EGF receptors [18]. Furthermore, Errasfa et al. [12] 
recently reported that PMA could directly activate PTPases 
in NIH-3T3 cells expressing EGF receptors. If the PTPases 
toward the EGF receptors’ tyrosine kinase was activated 
by PMA, then EGF receptors could be dephosphorylated 
accordingly. However, we could not detect any direct 
effects of PMA on the PTPase activity toward EGF recep- 
tors in non-stimulated A431 cells, while EGF stimulated 
PTPase activity [19]. Therefore, PTPase was likely be one 
of a EGF mediated signal and the activation of PTPase 
itself was not directly responsible for the PMA induced 
impairment of EGF receptor kinase in A431 cells. 
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